"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

That superhero is a gene called TP53, and for decades scientists have known it as the “guardian of the genome.” In a healthy cell, TP53 acts like both a brake and an emergency stop button. When DNA ...

A Korea University research study is claiming to have identified a mechanism that allows leukemia cells to survive despite excessive growth ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Our Lady of the Lake is reshaping the way Louisianans face blood cancers, combining revolutionary treatments such as stem cell transplants with advanced clinical research and holistic patient support.

SENTI-202, an off-the-shelf CAR NK cell therapy for AML, received FDA orphan drug designation, supporting its development for relapsed or refractory cases. LYL314, a CAR T-cell therapy for large ...

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

Syndax has received approval from the Food and Drug Administration for a treatment for a type of acute leukemia. The biopharmaceutical company said Friday the approval is for its Revuforj therapy to ...

The ASAP trial sets new perspectives on international therapy standards: High-dose chemotherapy is not always necessary before transplantation in cases of acute myeloid leukemia (AML). This means ...

In patients with Ph-positive disease, TKIs should be used continuously, which may lead to toxicities. This must be considered during therapy selection. The optimal duration of TKI maintenance is not ...